Protocol Ledger

NCT07172919 · Phase II · RECRUITING

A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation

Interventional Phase II clinical trial protocol NCT07172919 sponsored by Amgen in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-01-02 Enrollment: 14 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07172919
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)14 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07172919
Protocol FieldVerified Registry Value
NCT IdentifierNCT07172919
Consolidated Lead SponsorAmgen
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment14 participants (ESTIMATED)
Registered Start Date2026-01-02
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI